Virtual Library

Start Your Search

Hironori Izutani



Author of

  • +

    EP1.04 - Immuno-oncology (ID 194)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.04-27 - Expression Analysis of Programmed Death-Ligand (PD-L) 1 in Large Cell Neuroendocrine Carcinoma (Now Available) (ID 3112)

      08:00 - 18:00  |  Author(s): Hironori Izutani

      • Abstract
      • Slides

      Background

      Programmed death (PD)-1/PD-ligand-1 (PD-L1) signaling is main target of immune-checkpoint therapy for lung cancer. Since PD-L1 expression level is known as an important indicator for patient selection of PD-1/PD-L1 blockade therapy, immunohistochemical analysis using anti-PD-L1 antibody were largely performed in various lung cancer tissues. However, there was few evidences regarding expression pattern of PD-L1 in large cell neuroendocrine carcinoma (LCNEC). In this study, we aimed to clarify the tissue distribution of PD-L1, and gene expression pattern between PD-L1-positive and negative cells in LCNEC.

      Method

      Lung cancer tissues were derived from patients with LCNEC (n=10) and adenocarcinoma (n=8). All tissues were stained with anti-PD-L1 (SP142, Ventana/Roche), CD8 (T lymphocytes), and PD1 antibody using OptiView DAB IHC systems. To investigate the molecular mechanism of overexpression of PD-L1 in LCNEC, we have also performed microarray analysis of PD-L1-positive and -negative cancer cells in the identical LCNEC patient.

      Result

      From immunohistochemical staining data, while 25% of adenocarcinoma were PD-L1 positive, 80% of LCNEC were strongly stained by anti-PD-L1 antibody. Invasion of PD-1-positive lymphocytes were also seen around PD-L1 positive lung cancer cells. Microarray data showed that antigen-presenting related genes were dominantly up-regulated in the PD-L1-positive cells.

      Conclusion

      Our data concluded that the patients with LCNEC might be targets for immune-checkpoint therapy using anti-PD-1 neutralizing antibody.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.